CHO Plus, Inc.
Early-stage biotechnology company developing patented mammalian cell engineering technologies to increase productivity for therapeutic protein (mAb) and viral vector (AAV) manufacturing. The organization focuses on creating higher‑yield CHO and HEK‑293 host cells, screening/selection platforms, and stable producer cell lines with the intent to license the technology and partner with biopharma manufacturers.
Industries
Nr. of Employees
small (1-50)
Patents
Cell lines for high level production of protein selected for rapid proliferation
US-12723244-B2
View DetailsCell hybrids as virus packaging cells for high efficiency production of gene therapy vectors and viral vaccines
US-12252713-B2
View Details
Cell lines for high level production of protein selected for rapid proliferation
US-12723244-B2
View DetailsCell hybrids as virus packaging cells for high efficiency production of gene therapy vectors and viral vaccines
US-12252713-B2
View DetailsProducts
Engineered CHO host cell lines for high‑productivity mAb production
CHO host cell lines engineered and selected for increased ER content and specific productivity, demonstrated in transient and stably transfected clones at shake‑flask fed‑batch scale.
Engineered HEK‑293 host cell lines and producer cell lines for AAV production
HEK‑293 derived engineered host and producer cell lines selected for increased AAV capsid and functional titers across multiple serotypes and for improved percent‑full capsids.
Engineered CHO Cells
Genetically-engineered CHO cells capable of up to 10-fold higher protein productivity in model systems, achieving up to 13.5 g/l mAb in shake flasks and 117 pg/cell/day.
Engineered HEK-293 Cells
Engineered HEK-293 cells capable of over 20-fold AAV productivity improvement, with up to 55% full capsids, along with a stably-transfected inducible AAV packaging cell line.
Engineered CHO host cell lines for high‑productivity mAb production
CHO host cell lines engineered and selected for increased ER content and specific productivity, demonstrated in transient and stably transfected clones at shake‑flask fed‑batch scale.
Engineered HEK‑293 host cell lines and producer cell lines for AAV production
HEK‑293 derived engineered host and producer cell lines selected for increased AAV capsid and functional titers across multiple serotypes and for improved percent‑full capsids.
Engineered CHO Cells
Genetically-engineered CHO cells capable of up to 10-fold higher protein productivity in model systems, achieving up to 13.5 g/l mAb in shake flasks and 117 pg/cell/day.
Engineered HEK-293 Cells
Engineered HEK-293 cells capable of over 20-fold AAV productivity improvement, with up to 55% full capsids, along with a stably-transfected inducible AAV packaging cell line.
Services
Licensing of high‑productivity mammalian host cell lines for therapeutic protein and viral vector manufacture, under industry‑standard commercial terms.
Development and demonstration of engineered CHO and HEK‑293 cell lines for specific mAb or AAV production use cases, including fed‑batch testing and analytical characterization.
Licensing of high‑productivity mammalian host cell lines for therapeutic protein and viral vector manufacture, under industry‑standard commercial terms.
Development and demonstration of engineered CHO and HEK‑293 cell lines for specific mAb or AAV production use cases, including fed‑batch testing and analytical characterization.
Expertise Areas
- Mammalian cell line engineering
- Monoclonal antibody manufacturing (CHO)
- AAV and viral vector production (HEK‑293)
- Directed evolution and genome shuffling
Key Technologies
- Cell fusion–based genome shuffling
- Directed evolution screening platforms
- Transposase‑mediated stable integration
- Transient and stable mammalian transfection
News & Updates
Announcement of a U.S. patent related to improved production of viral vectors for gene therapy.
Announcement of a U.S. patent for improved production of proteins using engineered yeast cells.
Project agreement to develop high‑productivity cell lines for antibody manufacturing against filoviruses.
Selected for the 2025 BioTools Innovator Accelerator program.
Research collaboration agreement to advance commercialization of cell engineering technology.
U.S. patent issued (US 10,329,594) covering cell lines for high level production of protein‑based pharmaceuticals.
Announcement of a U.S. patent related to improved production of viral vectors for gene therapy.
Announcement of a U.S. patent for improved production of proteins using engineered yeast cells.
Project agreement to develop high‑productivity cell lines for antibody manufacturing against filoviruses.
Selected for the 2025 BioTools Innovator Accelerator program.
Research collaboration agreement to advance commercialization of cell engineering technology.
U.S. patent issued (US 10,329,594) covering cell lines for high level production of protein‑based pharmaceuticals.